Project/Area Number |
12671928
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Surgical dentistry
|
Research Institution | Tokyo Medical and Dental University |
Principal Investigator |
YAMAGUCHI Satoshi Tokyo Medical and Dental university, Graduate School, Assistant Professer, 大学院・医歯学総合研究科, 助手 (00280628)
|
Co-Investigator(Kenkyū-buntansha) |
YAMADA Shumpei Tokyo Medical and Dental university, Graduate School, Assistant Professer, 大学院・医歯学総合研究科, 助手 (60302890)
|
Project Period (FY) |
2000 – 2002
|
Project Status |
Completed (Fiscal Year 2002)
|
Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2002: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2001: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 2000: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
Keywords | Tissue engineering / bone / gene therapy / Scaffold / autoserum / 再生医学 |
Research Abstract |
The goals of this project is regeneration of bone by autotransplantation of osteoblastic cells derived from mesenchymal stem cells in bone marrow. We have performed studies as follows. (1)Bone regeneration by BMP2-gene transduced mesenchymal stem cells We generated recombinant retrovirus vector including human BMP2 cDNA. Primary cultured rat mesenchymal stem cells were differentiated into osteoblasts by retrovirus mediated gene transduction of BMP2. Histological analysis showed that the newly bone formation in vivo by transplantation of BMP2-transduced bone marrow stem cells seeded on hydroxyapatite. (2)Novel scaffold for bone regeneration We produced a poly (ethylene glycol)(PEG) hydrogel cross-linked by a hydrolyzable polyrotaxane containing hydroxyapatite particles (PRX-HAp). Osteoblasts were observed to attach and survive on the surface of PRX-HAp. Histological analysis showed that osteoid-like tissues were seen in the region between PRX-HAps and a queue of osteoblast-like cells. The PRX-HAps have the great potential for bone tissue engineering. (3)Expansion of human bone marrow stromal cells with patient's autologus serum To overcome the risk of bovine serum, we examined whether a patient's autologous serum could support the growth and differentiation of his/her bone marrow stromal cells (BMSCs). A patient's autologous serum could expand BMSCs without losing their potentiality for osteoblastic differentiation. Patients' autologous serum could be efficient to expand BMSCs and to be utilized safely for bone regeneration therapy.
|